Joincare Pharmaceutical Group Industry Co., Ltd

This Phase 2 trial tests a new biologic drug called JKN24011 in 215 people with moderate to severe COPD. Participants receive either the drug or a placebo as a shot under the skin every four weeks. The main goal is to see if the drug can reduce the number of moderate or severe CO…